SR One
SR One is a transatlantic biotechnology venture capital firm that partners with founders to translate innovative science into medicines. The firm describes a "back-and-build" investment approach and positions teams in West Coast USA and London to provide regional expertise and real-time business support to portfolio companies.
Services
Venture capital funding
Provides equity investment to biotechnology companies across clinical and preclinical stages.
Strategic and operational support
Provides business support and operational expertise to portfolio companies; the firm states it takes a "back-and-build" approach and has added venture partners to deepen operational expertise.
Transatlantic business support and regional expertise
Dedicated presence in West Coast USA and London to provide geographic reach and in-region support for portfolio companies.
Venture capital funding
Provides equity investment to biotechnology companies across clinical and preclinical stages.
Strategic and operational support
Provides business support and operational expertise to portfolio companies; the firm states it takes a "back-and-build" approach and has added venture partners to deepen operational expertise.
Transatlantic business support and regional expertise
Dedicated presence in West Coast USA and London to provide geographic reach and in-region support for portfolio companies.
Portfolio
Focus: whole-gene insertion technologies. Geography: South San Francisco, USA.
#Other
RNA targeting platform; CEO: Zhen Li, PhD. Geography: San Diego, USA.
#Rare diseases
Clinical-stage biologic treatments for oncology and inflammatory diseases. CEO: Ben Buelow, MD, PhD. Geography: Palo Alto, USA.
#Immunology
Developing next-generation TYK2 inhibitors for autoimmune diseases. CEO: Martin Babler. Geography: South San Francisco, CA.
#Immunology
Developing an epinephrine nasal spray for severe allergies. CEO: Richard Lowenthal. Geography: San Diego, USA.
#Immunology
Focus: whole-gene insertion technologies. Geography: South San Francisco, USA.
#Other
RNA targeting platform; CEO: Zhen Li, PhD. Geography: San Diego, USA.
#Rare diseases
Clinical-stage biologic treatments for oncology and inflammatory diseases. CEO: Ben Buelow, MD, PhD. Geography: Palo Alto, USA.
#Immunology
Developing next-generation TYK2 inhibitors for autoimmune diseases. CEO: Martin Babler. Geography: South San Francisco, CA.
#Immunology
Developing an epinephrine nasal spray for severe allergies. CEO: Richard Lowenthal. Geography: San Diego, USA.
#Immunology